Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

W hen Donald Trump’s tariffs are mentioned, you might recall his “Liberation Day” duties on uninhabited islands, his on-again ...

Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong second-quarter sales of key ...

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

Johnson and Johnson beat Wall Street’s quarterly sales expectations and raised its full-year outlook, a show of confidence as ...

Johnson & Johnson (NYSE:JNJ) is set to kick off the second quarter pharma earnings on Wednesday, with investors focusing on ...

The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed calls for a tariff ...

Australia’s pharmaceutical benefits scheme is not up for negotiation, says the federal government in the face of ramped-up US ...

Drugmaker Swedish Orphan Biovitrum AB’s Chief Executive Officer Guido Oelkers said he doesn’t think tariff threats on the ...

Already late with carrying out his administration's prior threats around pharmaceutical tariffs, President Donald Trump has ...

A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.

President Trump wants to place a 200 percent tariff on your pharmaceuticals. “We’ll be announcing something very soon on ...